AUTHORS
Anas Al-sadi, Carmel A R Awadallah, MD2, Shebli Atrash, MD3, Jessica McElwee, PharmD4, Grace Elsey, PharmD5, Donald C Moore, PharmD, BCOP6, Anas Zayad7, Zena Chahine, MD8, Anita Mazloom9, Prerna Mewawalla, MD10, Jivtesh Singh, MD11, Muhammad Mushtaq, MD12, Jeries Kort, MD13, Alma Habib, MD, MS14, Al-Ola Abdallah, MD15, Joseph P McGuirk, DO16, Zahra Mahmoudjafari, PharmD, BCOP17, Jordan Snyder, PharmD, BCOP18
AFFILIATIONS
1 Division of Internal Medicine, University of Missouri–Kansas City, Kansas City, Missouri, United States
2 St John's Episcopal Hospital, Far Rockaway, New York, United States
3 Levine Cancer Institute, Atrium Health, Wake Forest University School of Medicine, Charlotte, North Carolina, United States
4 Levine Cancer Institute, Atrium Health, Wake Forest University School of Medicine, Charlotte, North Carolina, United States
5 Levine Cancer Institute, Atrium Health, Wake Forest University School of Medicine, Charlotte, North Carolina, United States
6 Levine Cancer Institute, Atrium Health, Wake Forest University School of Medicine, Charlotte, North Carolina, United States
7 Department of Internal Medicine, Hamad Medical Corporation,, Doha, Qatar, Qatar
8 Division of Hematology and Marrow Transplantation, University of Kentucky, Lexington, Kentucky, United States
9 Division of Hematology and Oncology, Mitchell Cancer Institute, University of South Alabama, Mobile, Alabama, United States
10 Division of Hematology and Cellular Therapy, Allegheny Health Network Cancer Institute, Pittsburgh, Pennsylvania, United States
11 Division of Internal Medicine, Allegheny Health Network, Pittsburgh, Pennsylvania, United States
12 Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, Kansas, United States
13 Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, Kansas, United States
14 Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, Kansas, United States
15 Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, Kansas, United States
16 Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, Kansas, United States
17 Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, Kansas, United States
18 Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, Kansas, United States
ABSTRACT
Background
Infections remain a major cause of morbidity during BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma (RRMM). Despite the widespread implementation of intravenous immunoglobulin (IVIG), antimicrobial prophylaxis, and granulocyte colony-stimulating factor (G-CSF), it remains unclear whether these interventions independently reduce infection risk beyond the underlying patient immune dysfunction. We evaluated whether hypogammaglobulinemia and commonly used supportive care interventions were independently associated with infection risk.
Methods
We performed a multicenter retrospective study of 144 consecutive patients with RRMM treated with BCMA-directed bispecific antibodies between August 2022 and April 2026 at five academic centers. The collected data included antimicrobial prophylaxis (HSV, Pneumocystis jirovecii pneumonia [PJP], and other agents), IVIG replacement, G-CSF administration, hypogammaglobulinemia (IgG <400 mg/dL), neutropenia, and infectious outcomes. Univariate comparisons were performed using Fisher's exact and Wilcoxon rank-sum tests. Independent predictors of infection were evaluated using Firth penalized multivariable logistic regression analysis. To account for substantial interinstitutional variation, Mantel-Haenszel stratified analyses adjusted for the treatment center were also performed.
Results
Among the 144 patients, 62 (43.1%) developed at least one infection during follow-up. The overall infection incidence reached 40.1% at 3 months and 50.6% at 12 months. Infection incidence differed nearly 25-fold across participating centers (2.6%–64.1%), highlighting substantial heterogeneity in real-world supportive care practices and/or patient selection criteria.
Hypogammaglobulinemia (IgG <400 mg/dL) was significantly more common among patients who developed infection (74% vs 48%) and was the only independent predictor of infection in multivariable analysis (adjusted OR 3.40, 95% CI 1.57–7.59; p=0.002). This association remained robust after adjusting for center-level variation (Mantel-Haenszel OR 4.11, 95% CI 1.76–9.58; p<0.001).
Supportive care interventions were commonly employed, including intravenous immunoglobulin (IVIG) (56%), PJP prophylaxis (70%), HSV prophylaxis (95%), and granulocyte colony-stimulating factor (G-CSF) (18%). In the univariable analysis, patients receiving IVIG or G-CSF experienced numerically higher infection rates, consistent with preferential administration to patients with established hypogammaglobulinemia or other high-risk clinical features. After adjusting for patient characteristics and confounding by indication, neither IVIG, G-CSF (adjusted OR 0.98, 95% CI 0.39–2.44; p=0.964), nor PJP prophylaxis (adjusted OR 1.41, 95% CI 0.49–4.09; p=0.708) independently predicted infection. The apparent association with HSV prophylaxis reflected center-specific practice patterns rather than treatment effects. Age, sex, high-risk cytogenetics, and neutropenia were not independently associated with the risk of infection.
Early infections were predominantly bacterial (58.5% of all typed infections in the first 3 months), whereas viral infections predominated beyond 3 months (52.4% at 3–6 months and 62.5% at 6–12 months), suggesting that supportive care requirements may evolve over the course of treatment.
Conclusions
Hypogammaglobulinemia, not the receipt of supportive care interventions, was the dominant predictor of infection during BCMA-directed bispecific antibody therapy. Although IVIG replacement, antimicrobial prophylaxis, and G-CSF were frequently administered, these interventions were preferentially used in patients already at highest infectious risk and were not independently associated with lower infection rates after adjustment for confounding by indication and institutional practice variation.
These findings support standardized infection surveillance and biomarker-guided supportive care strategies centered on serial IgG monitoring, while underscoring the need for prospective studies to define optimal thresholds and timing for immunoglobulin replacement during BCMA-directed bispecific therapy.
DISCLOSURES
Carmel A R Awadallah, MD: No relevant conflicts of interest to declare.